NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies

Reuters

Jan 13

NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies

NanoViricides Inc. has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603568254"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603568254\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603568254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603568254","market":"nz","top_or_hot":-1,"title":"NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL1bCYq6:1","article_id":"2603568254","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603568254","pubTimestamp":1768311066,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NanoViricides Inc. has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4568":"美国抗疫概念","NNVC":"NanoViricides Inc."},"translate_title":"NanoViricides报告NV-387在动物研究中对抗H3N2的表现优于达菲和Xofluza","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NNVC":0.9},"content_text":"NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies\n    \n\nNanoViricides Inc. has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}